This study has provided some compelling evidence that liver tumor formation in mouse models of metabolic syndrome and NASH, and in patients with hepatocellular carcinoma with NASH background is closely linked to the activation of mTOR pathways. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatohepatitis.